Treatment patterns in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2023 - an updated analysis
Related Experiment Video
Updated: May 15, 2025

08:39
Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
4.5K
Mette Nørgaard1, Aurélie Mailhac2, Karin Fagerlund3
1Department of Clinical Epidemiology, Arhus University Hospital and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. mn@clin.au.dk.
Acta Oncologica (Stockholm, Sweden)
|May 8, 2025
Abstract
No abstract available in PubMed .
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
10.0K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.2K
Related Concept Videos
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Survival Analysis
308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308